Moran Wealth Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Moran Wealth Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-3,988	Closed	-$348K	–	392
2024 Q1	$348K	Buy	3,988 +1,638	+70%	+$147K	0.01%	367
2023 Q4	$227K	Buy	+2,350	New	+$208K	0.01%	391

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Moran Wealth Management's BMRN Position: Q2 2024 in Review

Moran Wealth Management sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2024, closing a stake of 3,988 shares — an estimated $348K sold.

Moran Wealth Management first reported a position in BMRN in Q4 2023 and held it in 2 quarters. The position peaked at $348K in Q1 2024. 558 funds tracked by Wall St. Rank hold BMRN as of Q2 2024.

Moran Wealth Management reported no remaining BioMarin Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Moran Wealth Management sold 3,988 BioMarin Pharmaceuticals shares in Q2 2024, an estimated $348K.
Moran Wealth Management first reported a position in BioMarin Pharmaceuticals in Q4 2023 and held it in 2 quarters.
Moran Wealth Management's BioMarin Pharmaceuticals position peaked at $348K in Q1 2024.
558 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2024.

Based on Moran Wealth Management's 13F filing for Q2 2024, filed 13 Aug 2024.